The American Journal of Surgery
Volume 191, Issue 4 , Pages 517-526 , April 2006

Colon cancer and apoptosis

Received 1 November 2005 ,Revised 28 November 2005

References 

  1. Jemal A , Murray T , Ward E , et al.   Cancer statistics, 2005 . CA Cancer J Clin . 2005;55:10–30
  2. Watanabe T , Wu TT , Catalano PJ , et al.   Molecular predictors of survival after adjuvant chemotherapy for colon cancer . N Engl J Med . 2001;344:1196–1206
  3. Scheithauer W , Rosen H , Kornek GV , et al.   Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer . Br Med J . 1993;306:752–755
  4. Meyerhardt JA , Mayer RJ . Systemic therapy for colorectal cancer . N Engl J Med . 2005;352:476–487
  5. Zhang ZG , Harstrick A , Rustum YM . Modulation of fluoropyrimidines (role of dose and schedule of leucovorin administration) . Semin Oncol . 1992;19:10–15
  6. de Gramont A , Figer A , Seymour M , et al.   Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer . J Clin Oncol . 2000;18:2938–2947
  7. Fuchs CS . Current and ongoing trials with irinotecan in the United States . Semin Oncol . 2003;30:9–17
  8. Iyer L , Ratain MJ . Clinical pharmacology of camptothecins . Cancer Chemother Pharmacol . 1998;42(suppl):S31–S43
  9. Goldberg RM , Sargent DJ , Morton RF , et al.   A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer . J Clin Oncol . 2004;22:23–30
  10. Raymond E , Faivre S , Woynarowski JM , et al.   Oxaliplatin (mechanism of action and antineoplastic activity) . Semin Oncol . 1998;25:4–12
  11. Hurwitz H , Fehrenbacher L , Novotny W , et al.   Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer . N Engl J Med . 2004;350:2335–2342
  12. Cummings MC , Winterford CM , Walker NI . Apoptosis . Am J Surg Pathol . 1997;21:88–101
  13. Kerr JF , Wyllie AH , Currie AR . Apoptosis (a basic biological phenomenon with wide-ranging implications in tissue kinetics) . Br J Cancer . 1972;26:239–257
  14. Subramanian T , Chinnadurai G . Pro-apoptotic activity of transiently expressed BCL-2 occurs independent of BAX and BAK . J Cell Biochem . 2003;89:1102–1114
  15. Borner C , Monney L . Apoptosis without caspases (an inefficient molecular guillotine?) . Cell Death Diff . 1999;6:497–507
  16. Leist M , Jaattela M . Four deaths and a funeral (from caspases to alternative mechanisms) . Nat Rev Mol Cell Biol . 2001;2:589–598
  17. Krammer PH . CD95’s deadly mission in the immune system . Nature . 2000;407:789–795
  18. Walczak H , Krammer PH . The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems . Exp Cell Res . 2000;256:58–66
  19. Adrain C , Martin SJ . The mitochondrial apoptosome (a killer unleashed by the cytochrome seas) . Trends Biochem Sci . 2001;26:390–397
  20. Chauhan D , Hideshima T , Rosen S , et al.   Apaf-1/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma (MM) cells . J Biol Chem . 2001;276:24453–24456
  21. Sperandio S , de Belle I , Bredesen DE . An alternative, nonapoptotic form of programmed cell death . Proc Natl Acad Sci USA . 2000;97:14376–14381
  22. Du C , Fang M , Li Y , et al.   Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition . Cell . 2000;102:33–42
  23. Mayo MW , Baldwin AS . The transcription factor NF-kappaB (control of oncogenesis and cancer therapy resistance) . Biochim Biophys Acta . 2000;1470:M55–M62
  24. Hakem R , Hakem A , Duncan GS , et al.   Differential requirement for caspase 9 in apoptotic pathways in vivo . Cell . 1998;94:339–352
  25. Yoshida H , Kong YY , Yoshida R , et al.   Apaf1 is required for mitochondrial pathways of apoptosis and brain development . Cell . 1998;94:739–750
  26. Varfolomeev EE , Schuchmann M , Luria V , et al.   Targeted disruption of the mouse caspase 8 gene ablates cell death induction by the TNF receptors Fas/Apo1 and DR3 and is lethal prenatally . Immunity . 1998;9:267–276
  27. Yeh WC , Pompa JL , McCurrach ME , et al.   FADD (essential for embryo development and signaling from some, but not all, inducers of apoptosis) . Science . 1998;279:1954–1958
  28. Roy S , Nicholson DW . Cross-talk in cell death signaling . J Exp Med . 2000;192:21–26
  29. Slee EA , Adrain C , Martin SJ . Serial killers (ordering caspase activation events in apoptosis) . Cell Death Differ . 1999;6:1067–1074
  30. Jaattela M . Escaping cell death (survival proteins in cancer) . Exp Cell Res . 1999;248:30–43
  31. Zhivotovsky B , Orrenius S . Defects in the apoptotic machinery of cancer cells (role in drug resistance) . Semin Cancer Biol . 2003;13:125–134
  32. Broker LE , Kruyt FA , Giaccone G . Cell death independent of caspases (a review) . Clin Cancer Res . 2005;11:3155–3162
  33. McDonnell TJ . Cell division versus cell death (a functional model of multistep neoplasia) . Mol Carcinog . 1993;8:209–213
  34. Hockenbery DM , Zutter M , Hickey W , et al.   BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death . Proc Natl Acad Sci U S A . 1991;88:6961–6965
  35. Butler LM , Hewett PJ , Fitridge RA , et al.   Deregulation of apoptosis in colorectal carcinoma (theoretical and therapeutic implications) . Aust N Z J Surg . 1999;69:88–94
  36. Rupnarain C , Dlamini Z , Naicker S , et al.   Colon cancer (genomics and apoptotic events) . Biol Chem . 2004;385:449–464
  37. Anti M , Armuzzi A , Morini S , et al.   Severe imbalance of cell proliferation and apoptosis in the left colon and in the rectosigmoid tract in subjects with a history of large adenomas . Gut . 2001;48:238–246
  38. Bedi A , Pasricha PJ , Akhtar AJ , et al.   Inhibition of apoptosis during development of colorectal cancer . Cancer Res . 1995;55:1811–1816
  39. Greco C , Alvino S , Buglioni S , et al.   Activation of c-MYC and c-MYB proto-oncogenes is associated with decreased apoptosis in tumor colon progression . Anticancer Res . 2001;21:3185–3192
  40. Valentini AM , Caruso ML , Armentano R , et al.   Programmed cell death in colorectal carcinogenesis . Anticancer Res . 1999;19:3019–3024
  41. Hawkins N , Lees J , Hargrave R , et al.   Pathological and genetic correlates of apoptosis in the progression of colorectal neoplasia . Tumour Biol . 1997;18:146–156
  42. Koike M . Significance of spontaneous apoptosis during colorectal tumorigenesis . J Surg Oncol . 1996;62:97–108
  43. O’Connell J , Bennett MW , Nally K , et al.   Altered mechanisms of apoptosis in colon cancer (Fas resistance and counterattack in the tumor-immune conflict) . Ann N Y Acad Sci . 2000;910:178–192
  44. Van Geelen CM , de Vries EG , de Jong S . Lessons from TRAIL-resistance mechanisms in colorectal cancer cells (paving the road to patient-tailored therapy) . Drug Resist Updat . 2004;7:345–358
  45. Itoh N , Yonehara S , Ishii A , et al.   The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis . Cell . 1991;66:233–243
  46. O’Connell J , Bennett MW , O’Sullivan GC , et al.   Fas ligand expression in primary colon adenocarcinomas (evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer) . J Pathol . 1998;186:240–246
  47. Moller P , Koretz K , Leithauser F , et al.   Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium . Int J Cancer . 1994;57:371–377
  48. Wiley SR , Schooley K , Smolak PJ , et al.   Identification and characterization of a new member of the TNF family that induces apoptosis . Immunity . 1995;3:673–682
  49. Koornstra JJ , Kleibeuker JH , Van Geelen CM , et al.   Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas . J Pathol . 2003;200:327–335
  50. Strater J , Hinz U , Walczak H , et al.   Expression of TRAIL and TRAIL receptors in colon carcinoma (TRAIL-R1 is an independent prognostic parameter) . Clin Cancer Res . 2002;8:3734–3740
  51. Griffith TS , Chin WA , Jackson GC , et al.   Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells . J Immunol . 1998;161:2833–2840
  52. Strater J , Walczak H , Pukrop T , et al.   TRAIL and its receptors in the colonic epithelium (a putative role in the defense of viral infections) . Gastroenterology . 2002;122:659–666
  53. Takeda K , Smyth MJ , Cretney E , et al.   Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development . J Exp Med . 2002;195:161–169
  54. Ilyas M , Straub J , Tomlinson IP , et al.   Genetic pathways in colorectal and other cancers . Eur J Cancer . 1999;35:1986–2002
  55. LeBlanc H , Lawrence D , Varfolomeev E , et al.   Tumor-cell resistance to death receptor–induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax . Nat Med . 2002;8:274–281
  56. Cummins JM , Kohli M , Rago C , et al.   X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells . Cancer Res . 2004;64:3006–3008
  57. Krueger A , Baumann S , Krammer PH , et al.   FLICE-inhibitory proteins (regulators of death receptor-mediated apoptosis) . Mol Cell Biol . 2001;21:8247–8254
  58. Longley DB, Wilson TR, McEwan M, et al. c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene [advance online publication]. Available at: http://www.nature.com/onc/journal/vaop/ncurrent/abs/1209122a.html. Accessed January 9, 2005.
  59. Kataoka T , Budd RC , Holler N , et al.   The caspase-8 inhibitor FLIP promotes activation of NF-kappaB and Erk signaling pathways . Curr Biol . 2000;10:640–648
  60. Naito M , Katayama R , Ishioka T , et al.   Cellular FLIP inhibits beta-catenin ubiquitylation and enhances Wnt signaling . Mol Cell Biol . 2004;24:8418–8427
  61. Vousden KH . Activation of the p53 tumor suppressor protein . Biochim Biophys Acta . 2002;1602:47–59
  62. Forslund A , Lonnroth C , Andersson M , et al.   Mutations and allelic loss of p53 in primary tumor DNA from potentially cured patients with colorectal carcinoma . J Clin Oncol . 2001;19:2829–2836
  63. Shaw P , Bovey R , Tardy S , et al.   Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line . Proc Natl Acad Sci USA . 1992;89:4495–4499
  64. Fazeli A , Steen RG , Dickinson SL , et al.   Effects of p53 mutations on apoptosis in mouse intestinal and human colonic adenomas . Proc Natl Acad Sci USA . 1997;94:10199–10204
  65. Lassus P , Opitz-Araya X , Lazebnik Y . Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization . Science . 2002;297:1352–1354
  66. Jiang M , Milner J . Bcl-2 constitutively suppresses p53-dependent apoptosis in colorectal cancer cells . Genes Dev . 2003;17:832–837
  67. Saleh HA , Jackson H , Banerjee M . Immunohistochemical expression of bcl-2 and p53 oncoproteins (correlation with Ki67 proliferation index and prognostic histopathologic parameters in colorectal neoplasia) . Appl Immunohistochem Mol Morphol . 2000;8:175–182
  68. Hoffman WH , Biade S , Zilfou JT , et al.   Transcriptional repression of the anti-apoptotic survivin gene by wild type p53 . J Biol Chem . 2002;277:3247–3257
  69. Fodde R , Smits R , Clevers H . APC, signal transduction and genetic instability in colorectal cancer . Nat Rev Cancer . 2001;1:55–67
  70. Senda T , Shimomura A , Iizuka-Kogo A . Adenomatous polyposis coli (Apc) tumor suppressor gene as a multifunctional gene . Anat Sci Int . 2005;80:121–131
  71. He TC , Sparks AB , Rago C , et al.   Identification of c-MYC as a target of the APC pathway . Science . 1998;281:1509–1512
  72. Krajewska M , Moss SF , Krajewski S , et al.   Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas . Cancer Res . 1996;56:2422–2427
  73. Watson AJ , Merritt AJ , Jones LS , et al.   Evidence of reciprocity of bcl-2 and p53 expression in human colorectal adenomas and carcinomas . Br J Cancer . 1996;73:889–895
  74. Sturm I , Kohne CH , Wolff G , et al.   Analysis of the p53/BAX pathway in colorectal cancer (low BAX is a negative prognostic factor in patients with resected liver metastases) . J Clin Oncol . 1999;17:1364–1374
  75. Zhang L , Yu J , Park BH , et al.   Role of BAX in the apoptotic response to anticancer agents . Science . 2000;290:989–992
  76. Violette S , Poulain L , Dussaulx E , et al.   Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status . Int J Cancer . 2002;98:498–504
  77. Ravi R , Bedi A . Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers (synergism with sulindac-mediated inhibition of Bcl-x(L)) . Cancer Res . 2002;62:1583–1587
  78. Sevilla L , Zaldumbide A , Pognonec P , et al.   Transcriptional regulation of the bcl-x gene encoding the anti-apoptotic Bcl-xL protein by Ets, Rel/NFkappaB, STAT and AP1 transcription factor families . Histol Histopathol . 2001;16:595–601
  79. Cusack JC . Overcoming antiapoptotic responses to promote chemosensitivity in metastatic colorectal cancer to the liver . Ann Surg Oncol . 2003;10:852–862
  80. Kawasaki H , Altieri DC , Lu CD , et al.   Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer . Cancer Res . 1998;58:5071–5074
  81. Williams NS , Gaynor RB , Scoggin S , et al.   Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference . Clin Cancer Res . 2003;9:931–946
  82. Sarela AI , Scott N , Ramsdale J , et al.   Immunohistochemical detection of the anti-apoptosis protein, survivin, predicts survival after curative resection of stage II colorectal carcinomas . Ann Surg Oncol . 2001;8:305–310
  83. Yamamoto Y , Yin MJ , Lin KM , et al.   Sulindac inhibits activation of the NF-kappaB pathway . J Biol Chem . 1999;274:27307–27314
  84. Zhang T , Fields JZ , Ehrlich SM , et al.   The chemopreventive agent sulindac attenuates expression of the antiapoptotic protein survivin in colorectal carcinoma cells . J Pharmacol Exp Ther . 2004;308:434–437
  85. Fujie Y , Yamamoto H , Ngan CY , et al.   Oxaliplatin, a potent inhibitor of survivin, enhances paclitaxel-induced apoptosis and mitotic catastrophe in colon cancer cells . Jpn J Clin Oncol . 2005;35:453–463
  86. Urbano A , Lakshmanan U , Choo PH , et al.   AIF suppresses chemical stress-induced apoptosis and maintains the transformed state of tumor cells . EMBO J . 2005;24:2815–2826
  87. Onoda T , Ono T , Dhar DK , et al.   Tetracycline analogues (doxycycline and COL-3) induce caspase-dependent and -independent apoptosis in human colon cancer cells . Int J Cancer . 2005;118: in press
  88. Park YC , Jeong JH , Park KJ , et al.   Sulindac activates nuclear translocation of AIF, DFF40 and endonuclease G but not induces oligonucleosomal DNA fragmentation in HT-29 cells . Life Sci . 2005;77:2059–2070
  89. Erhart LM , Lankat-Buttgereit B , Schmidt H , et al.   Flavone initiates a hierarchical activation of the caspase-cascade in colon cancer cells . Apoptosis . 2005;10:611–617
  90. Basu S , Kolesnick R . Stress signals for apoptosis (ceramide and c-Jun kinase) . Oncogene . 1998;17:3277–3285
  91. Lavie Y , Cao H , Bursten SL , et al.   Accumulation of glucosylceramides in multidrug-resistant cancer cells . J Biol Chem . 1996;271:19530–19536
  92. Ruemmele FM , Schwartz S , Seidman EG , et al.   Butyrate induced Caco-2 cell apoptosis is mediated via the mitochondrial pathway . Gut . 2003;52:94–100
  93. Kim YH , Park JW , Lee JY , et al.   Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells . Carcinogenesis . 2004;25:1813–1820
  94. Schroder CP , Maurer HR . Tributyrin-induced differentiation promotes apoptosis of LS 174T colon cancer cells in vitro . Int J Oncol . 2002;20:195–200
  95. Jarry A , Vallette G , Cassagnau E , et al.   Interleukin 1 and interleukin 1beta converting enzyme (caspase 1) expression in the human colonic epithelial barrier. Caspase 1 downregulation in colon cancer . Gut . 1999;45:246–251
  96. Shureiqi I , Jiang W , Zuo X , et al.   The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-delta to induce apoptosis in colorectal cancer cells . Proc Natl Acad Sci USA . 2003;100:9968–9973
  97. Janne PA , Mayer RJ . Chemoprevention of colorectal cancer . N Engl J Med . 2000;342:1960–1968
  98. Holt SE , Shay JW . Role of telomerase in cellular proliferation and cancer . J Cell Physiol . 1999;180:10–18
  99. Kondo S , Tanaka Y , Kondo Y , et al.   Antisense telomerase treatment (induction of two distinct pathways, apoptosis and differentiation) . FASEB J . 1998;12:801–811
  100. Kakugawa Y , Wada T , Yamaguchi K , et al.   Up-regulation of plasma membrane-associated ganglioside sialidase (Neu3) in human colon cancer and its involvement in apoptosis suppression . Proc Natl Acad Sci USA . 2002;99:10718–10723
  101. Rao CV . Nitric oxide signaling in colon cancer chemoprevention . Mutat Res . 2004;555:107–119
  102. Backus HH , Van Groeningen CJ , Vos W , et al.   Differential expression of cell cycle and apoptosis related proteins in colorectal mucosa, primary colon tumours, and liver metastases . J Clin Pathol . 2002;55:206–211
  103. Mann B , Gratchev A , Bohm C , et al.   FasL is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas . Br J Cancer . 1999;79:1262–1269

PII: S0002-9610(05)00869-X

doi: 10.1016/j.amjsurg.2005.11.009

The American Journal of Surgery
Volume 191, Issue 4 , Pages 517-526 , April 2006

Article Tools

* Image Usage & Resolution